webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More
  1. Home
  2. Products
  3. ADC Linker
  4. Cleavable Linker
  5. diSPhMC-Asn-Pro-Val-PABC-MMAE

diSPhMC-Asn-Pro-Val-PABC-MMAE

  CAS No.: 2893871-68-4   Cat No.: BADC-01727 4.5  

diSPhMC-Asn-Pro-Val-PABC-MMAE is a cleavable peptide-based ADC linker designed for precise enzymatic cleavage and controlled payload release in antibody-drug conjugates, enhancing therapeutic efficacy. Keywords: ADC linker, cleavable linker, peptide linker, enzyme-sensitive, MMAE payload.

diSPhMC-Asn-Pro-Val-PABC-MMAE

Structure of 2893871-68-4

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C83H115N11O16S2
Molecular Weight
1587.00

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
IUPAC Name
[4-[[(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[6-[2,5-dioxo-3,4-bis(phenylsulfanyl)pyrrol-1-yl]hexanoylamino]-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate
Canonical SMILES
CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(C)C(C2=CC=CC=C2)O)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)N(C)C(=O)OCC3=CC=C(C=C3)NC(=O)C(C(C)C)NC(=O)C4CCCN4C(=O)C(CC(=O)N)NC(=O)CCCCCN5C(=O)C(=C(C5=O)SC6=CC=CC=C6)SC7=CC=CC=C7
InChI
InChI=1S/C83H115N11O16S2/c1-15-52(8)70(63(108-13)47-66(97)92-44-28-36-61(92)72(109-14)53(9)75(99)85-54(10)71(98)56-30-20-16-21-31-56)90(11)80(104)68(50(4)5)89-78(102)69(51(6)7)91(12)83(107)110-48-55-39-41-57(42-40-55)86-77(101)67(49(2)3)88-76(100)62-37-29-45-93(62)79(103)60(46-64(84)95)87-65(96)38-26-19-27-43-94-81(105)73(111-58-32-22-17-23-33-58)74(82(94)106)112-59-34-24-18-25-35-59/h16-18,20-25,30-35,39-42,49-54,60-63,67-72,98H,15,19,26-29,36-38,43-48H2,1-14H3,(H2,84,95)(H,85,99)(H,86,101)(H,87,96)(H,88,100)(H,89,102)/t52-,53+,54+,60-,61-,62-,63+,67-,68-,69-,70-,71+,72+/m0/s1
InChIKey
MADBCUVZKCPOGY-LQYUVZCHSA-N

diSPhMC-Asn-Pro-Val-PABC-MMAE, a synthetic peptide-drug conjugate (PDC) customized for precise cancer therapy, unveils a plethora of applications within the oncology domain. Here are four key applications:

Targeted Cancer Therapy: The meticulously engineered diSPhMC-Asn-Pro-Val-PABC-MMAE zeroes in on cancer cells with unparalleled accuracy while preserving the integrity of healthy tissues. The peptide component steers the conjugate towards specific cancer markers, ensuring the direct delivery of the potent MMAE payload to malignant cells. This precise targeting not only mitigates side effects but also amplifies the efficacy of cancer treatments.

Antibody-Drug Conjugate Research: Embedded as a pivotal element in the advancement of antibody-drug conjugates (ADCs), diSPhMC-Asn-Pro-Val-PABC-MMAE merges the selectivity of antibodies with the potency of cytotoxic drugs. Scientists harness this compound to scrutinize the stability, effectiveness, and safety of prospective ADCs. These discoveries play a pivotal role in sculpting more robust and secure cancer therapies.

Combination Therapy Studies: In the domain of cancer investigation, diSPhMC-Asn-Pro-Val-PABC-MMAE emerges as an indispensable instrument for exploring innovative combination therapies. By amalgamating this conjugate with other therapeutic compounds, researchers can evaluate synergistic effects and fine-tune treatment protocols. This method has the potential to enhance treatment outcomes and circumvent the development of drug resistance.

Pharmacokinetic and Pharmacodynamic (PK/PD) Analysis: Researchers leverage diSPhMC-Asn-Pro-Val-PABC-MMAE for intricate PK/PD analyses to unravel its distribution, metabolism, elimination in the body, and its molecular-level mode of action. These analyses play a crucial role in determining optimal dosage regimens and maximizing therapeutic efficiency while minimizing adverse effects.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Calculate
The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Calculate

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC Cytotoxin with Linker

ADC Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

ADC Linker

Precise Conjugation For Success

Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Biotin-PEG1-NH2 | DM3-SMe | DBCO-PEG4-DMEA-PNU159682 | SPDB | Biotin-PEG4-OH | (2S,4R)-N-((S)-2-(tert-Butyl)-17-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecan-1-oyl)-4-hydroxy-1-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide | CBT-161 | Streptonigrin | Mal-PEG4-NHS | Phe-Lys(Fmoc)-PAB | diSPhMC-Asn-Pro-Val-PABC-MMAE
Send Inquiry
Verification code
Inquiry Basket
loading Loading ......
Delete selectedGo to checkout